Navigation Links
Ranbaxy Signs Agreement With Zenotech For Cancer Drugs

Pharma major Ranbaxy Laboratories Ltd today said its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc (RPI) has signed an agreement //with Hyderabad-based Zenotech Laboratories Ltd to market generic cancer drugs in the US and Canada.

Under the agreement, Zenotech Labs would develop, submit for regulatory approval and manufacture a total of 11 oncology products. Ranbaxy would market these products as generic formulations in the US and Canadian markets under the Ranbaxy label, the company said in a statement.

'We anticipate a number of additional products materialising in the days ahead as a result of this mutually beneficial partnership,' Ranbaxy's CEO and Managing Director Malvinder M Singh said.

The combined branded sales of the products that the two companies have agreed upon is estimated to be about 3.7 billion dollars.

Zenotech is a specialty generic injectables company with a biotech core and has full fledged research and development facilities in India and the US. Its oncology and biologics manufacturing facilities are located in India.

'This strategic initiative by RPI will establish our presence in the therapeutic arena by offering a basket of products in the US and Canadian markets that has breadth and depth in the management of patients diagnosed with cancer,' Ranbaxy Inc President - Corporate Development Dipak Chattraj said.

(Source:PTI News)
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Mediaplanet is ... Wound Care" campaign in USA Today, which will educate readers on how to take ... the campaign, a large focus is placed on melanoma. Dancing with the Stars professional, ...
(Date:5/26/2017)... , ... May 26, 2017 , ... ... of the CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface ... browser-based interface for diagnostic device operations. With this platform, initializing devices and importing ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on ... continue to be available at a discounted crowdfunding price on Indiegogo . , ... are, I also wanted to bring a fidget toy to the market that was ...
(Date:5/26/2017)... ... ... “When the Stars Lead Home”: a poignant story of loss, determination, and perseverance. “When ... avid reader who lives in the Pacific Northwest with her husband, daughter, two dogs, ... She couldn’t be more grateful. , Twelve-year old Tizzy could not believe how quickly ...
(Date:5/26/2017)... ... , ... Water damage to the flooring of several classrooms at The Fort ... with a number of critical issues to address before students could return to classes. ... little or no disruption to class schedules. Second, the project had to comply with ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017 Global Health Intelligence (GHI), ... America , published its 2017 ranking of the ... on extensive data analysis from GHI,s hospitals database for ... for the region. The GHI database covers 86% of the ... than 130 data points for each institution in key areas ...
(Date:5/10/2017)... 2017 CSSi, the global leader in patient ... industry, is proud to announce the launch of its ... features both enriched content and a customized layout that ... company,s already well-established position as the top global patient ... many months of hard work, we are delighted to ...
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
Breaking Medicine Technology: